PL397314A1 - Process for the preparation of the dimethacrylated resin, especially for bone cement - Google Patents

Process for the preparation of the dimethacrylated resin, especially for bone cement

Info

Publication number
PL397314A1
PL397314A1 PL397314A PL39731411A PL397314A1 PL 397314 A1 PL397314 A1 PL 397314A1 PL 397314 A PL397314 A PL 397314A PL 39731411 A PL39731411 A PL 39731411A PL 397314 A1 PL397314 A1 PL 397314A1
Authority
PL
Poland
Prior art keywords
stage
bone cement
resin
dianhydro
sorbitol
Prior art date
Application number
PL397314A
Other languages
Polish (pl)
Other versions
PL216356B1 (en
Inventor
Jan Lukaszczyk
Bartosz Janicki
Original Assignee
Politechnika Slaska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Politechnika Slaska filed Critical Politechnika Slaska
Priority to PL397314A priority Critical patent/PL216356B1/en
Publication of PL397314A1 publication Critical patent/PL397314A1/en
Publication of PL216356B1 publication Critical patent/PL216356B1/en

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Dental Preparations (AREA)

Abstract

Sposób otrzymywania zywicy dimetakrylanowej zwlaszcza do cementu kostnego polega na tym, ze wykorzystuje sie 1,4:3,6-dianhydro-D-sorbitol (izosorbit), który w pierwszym etapie przeksztalca sie w eter diallilowy w reakcji eteryfikacji Williamsona z wykorzystaniem nadmiaru bromku allilu, korzystnie w temperaturze jego wrzenia, i stezonego wodnego roztworu zasady oraz katalitycznej ilosci katalizatora przeniesienia fazowego korzystnie bromku tetrabutyloamoniowego, który to eter diallilowy w drugim etapie przeksztalca sie w eter diglicydylowy z wykorzystaniem nadmiaru utleniacza, korzystnie utleniacza nieorganicznego o wzorze 2KHSO5 • KHSO4 • K2SO4, oraz acetonu i wodnego roztworu NaHCO3 w temperaturze do 50°C, który to eter diglicydylowy w trzecim etapie poddaje sie reakcji z kwasem metakrylowym, korzystnie z jego stechiometryczna iloscia w temperaturze do 150°C, i tym samym otrzymuje sie zywice dimetakrylanowa, której glównym skladnikiem jest 2,5-bis(2-hydroksy-3-metakryloksypropoksy)-1,4:3,6-dianhydro-D-sorbitol o wzorze 1.The method of obtaining dimethacrylate resin, especially for bone cement, is that 1,4: 3,6-dianhydro-D-sorbitol (isosorbitol) is used, which in the first stage transforms into diallyl ether in the Williamson etherification reaction using excess allyl bromide , preferably at its boiling point, and a concentrated aqueous base solution and a catalytic amount of phase transfer catalyst, preferably tetrabutylammonium bromide, which diallyl ether is transformed into diglycidyl ether in the second stage using an excess of oxidant, preferably an inorganic oxidant with the formula 2KHSO5 • KHSO4 • K2SO4 and acetone and an aqueous NaHCO3 solution at a temperature of up to 50 ° C, which diglycidyl ether in the third stage is reacted with methacrylic acid, preferably with its stoichiometric amount at a temperature of up to 150 ° C, and thus a dimethacrylate resin, the main component of which is obtained is 2,5-bis (2-hydroxy-3-methacryloxy) propoxy) -1.4: 3,6-dianhydro-D-sorbitol of formula 1.

PL397314A 2011-12-09 2011-12-09 Process for the preparation of the dimethacrylated resin, especially for bone cement PL216356B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL397314A PL216356B1 (en) 2011-12-09 2011-12-09 Process for the preparation of the dimethacrylated resin, especially for bone cement

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL397314A PL216356B1 (en) 2011-12-09 2011-12-09 Process for the preparation of the dimethacrylated resin, especially for bone cement

Publications (2)

Publication Number Publication Date
PL397314A1 true PL397314A1 (en) 2013-06-10
PL216356B1 PL216356B1 (en) 2014-03-31

Family

ID=48539616

Family Applications (1)

Application Number Title Priority Date Filing Date
PL397314A PL216356B1 (en) 2011-12-09 2011-12-09 Process for the preparation of the dimethacrylated resin, especially for bone cement

Country Status (1)

Country Link
PL (1) PL216356B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025058466A1 (en) * 2023-09-14 2025-03-20 한국화학연구원 Isosorbide-based diepoxide compound and method for preparing same

Also Published As

Publication number Publication date
PL216356B1 (en) 2014-03-31

Similar Documents

Publication Publication Date Title
BRPI0918476B8 (en) asymmetric pyrrolobenzodiazepine dimer compounds and their use to treat a proliferative disease
CL2008001674A1 (en) Simple variable domain (dab) of vascular endotlial growth anti-fator immunoglobulin (vegf); nucleoic acid that encodes it; vector and host cell; Method of production; antagonist of vegf comprising the dab; composition comprising the antagonist; and use of the antagonist to prepare a medication.
CL2009000379A1 (en) Specific isolated monoclonal antibody against angiopoietin 1 and 2 ligands of the tie 2 receptor; fragment thereof; nucleic acid molecule that encodes it; vector; host cell; Preparation method; pharmaceutical composition that includes it; and its use to inhibit unwanted angiogenesis such as cancer.
BR112013004481A2 (en) method for the synthesis of substituted hexitols such as dianhydrogalactitol
CO6721004A2 (en) Polymer made from maleic acid, allyl ether and vinyl acetate and the preparation and use of said polymer
CL2011000730A1 (en) Selection procedure for anti-cxcr4 antibodies and selected antibodies; nucleic acid encoding the antibodies; vector; host cell; production procedure; hybridoma that produces the antibodies; composition; use of selected antibodies to prepare a medicine to treat cancer.
MX340491B (en) Polymer of maleic acid, allyl ether and (meth)acrylic acid compounds, and preparation and use thereof.
BR112015027527A2 (en) counterpart zeste 2 inhibitor enhancer
PE20151920A1 (en) BINDING MOLECULES FOR BCMA AND CD3
CY1118725T1 (en) STABLE IRON-OLIGOSAKHARITE UNION
BR112012016376A2 (en) substituted pyrrolo-aminopyrimide compounds
MY174025A (en) Azole silane compound, surface treatment solution, surface treatment method, and use thereof
CL2016000284A1 (en) Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof.
CL2011002003A1 (en) Humanized antibody or fragments thereof, which bind to the epidermal growth factor receptor (egfr) in an aberrant expression or truncated egfr? 2-7; host cell; pharmaceutical composition comprising it; and its use to treat cancer.
IN2012DN00790A (en)
CL2014000631A1 (en) Binding molecule that binds to cd134 (ox40); nucleic acid molecule that encodes it; vector; host cell; Preparation process; pharmaceutical composition that includes it; and its use to treat cancer.
MX379386B (en) Glycoconjugation process
EA201300256A1 (en) ANTIBODIES TO THE RECEPTOR EPIDERMAL GROWTH-3 FACTOR (HER3)
EA201070343A1 (en) SIMPLE HYDROXIMETYL FURFURAL ETHERS OF SUGARS OR HMF AND MIXED ALCOHOLS
BR112015008037A2 (en) compounds, process for preparing a compound, pharmaceutical composition, use of the compound, method for treating cancer and invention
CL2013000868A1 (en) Isolated antibody that binds to the human cytomegalovirus (hcmv) complex or hcmv gh; nucleic acid encoding it; host cell; Method of production; composition that includes it; and its use to treat, inhibit or prevent hcmv infection.
BR112014027620A2 (en) formulation, use of a formulation, process for making a formulation, compound, and process for preparing a compound
AR098798A1 (en) PROCEDURE FOR THE DIAZOTIZATION OF 2,5-DICLOROANILINES
CO6351779A2 (en) SMALL MOLECULA INHIBITORS OF THE ANDROGEN RECEPTOR N-TERMINAL ACTIVATION
BR112015026441A2 (en) improved fullerene derivatives and related materials, methods and devices